Recursion Pharmaceuticals, Inc. (RXRX) AI Stock Analysis

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that combines biology, chemistry, automation, data science, and engineering to discover and develop therapeutic treatments. Headquartered in Salt Lake City, Utah, its clinical pipeline includes REC-994 in Phase IIa trials for cerebral cavernous malformation, REC-2282 for neurofibromatosis type 2, REC-4881 for familial adenomatous polyposis, and REC-3599 in Phase I trials for GM2 gangliosidosis. It also pursues various preclinical candidates addressing oncology, inflammation, and colitis. Recursion maintains strategic research collaborations with partners including Bayer AG, Takeda Pharmaceutical Company Limited, Chromaderm, Inc., the University of Utah Research Foundation, and Ohio State Innovation Foundation.

Revenue rose from $10.0M in FY2021 to $74.7M in FY2025, reflecting a 5-year revenue CAGR of 85.4%. However, profitability remained deeply negative. Operating margin was -867.9% in FY2025, and net income was -$644.8M, compared with -$178.1M in FY2021. Research and development expenses escalated steadily over this period, reaching $425.3M in FY2025 from $135.3M in FY2021. For the trailing twelve months ended June 30, 2026, revenue stood at $54.9M with an operating margin of -1759.7% and EPS of -$1.09. In the quarter ended June 30, 2026, revenue fell 60.1% year-over-year.

As of June 30, 2026, Recursion held $545.7M in cash and short-term investments against total debt of $61.9M, yielding a net cash position of $483.8M. Total assets were $1.21B, and shareholders' equity was $915.0M. The company has a current ratio of 5.03 and a debt-to-equity ratio of 0.07. Free cash flow was -$378.3M in FY2025, reflecting operational cash burn and $6.5M in capital expenditures. Share count increased by 214.4% over the past 5 years.

At $3.46 per share, Recursion holds a market capitalization of $1.86B and an enterprise value of $1.52B. The stock trades at a price-to-sales multiple of 33.9x and an enterprise value-to-revenue multiple of 28.3x, both well above the 4.1x price-to-sales ratio for the median of its US-listed Healthcare peers. Its price-to-book ratio is 2.2x. Over the past year, RXRX shares fell 45.5%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 81.8%, compared to an 83.0% gain for the index.

Wall Street coverage includes 1 Strong Buy, 2 Buys, and 4 Holds, with no Sell or Strong Sell ratings. The mean price target is $7.32, which is 111.2% above the last close of $3.46. For the fiscal year ending December 31, 2026, analysts estimate revenue of $41.8M and EPS of -$0.93. For FY2027, 7 analysts project revenue of $53.0M and EPS of -$0.87. Recursion has beaten EPS estimates in 3 of the last 4 quarters, with its next earnings release scheduled for November 4, 2026.

This page is an AI-written research summary of Recursion Pharmaceuticals, Inc. (RXRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RXRX income statement, RXRX balance sheet, RXRX key metrics, RXRX analyst forecast, RXRX chart. See the RXRX stock overview for the latest quote and news.